000078839 001__ 78839
000078839 005__ 20200716101425.0
000078839 0247_ $$2doi$$a10.1038/s41408-019-0176-x
000078839 0248_ $$2sideral$$a111193
000078839 037__ $$aART-2019-111193
000078839 041__ $$aeng
000078839 100__ $$aRodríguez-Otero, P.
000078839 245__ $$aPredicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
000078839 260__ $$c2019
000078839 5060_ $$aAccess copy available to the general public$$fUnrestricted
000078839 5203_ $$aDisease control at 5 years would be a desirable endpoint for elderly multiple myeloma (MM) patients, but biomarkers predicting this are not defined. Therefore, to gain further insights in this endpoint, a population of 498 newly diagnosed transplant-ineligible patients enrolled in two Spanish trials (GEM2005MAS65 and GEM2010MAS65), has been analyzed. Among the 435 patients included in this post-hoc study, 18.6% remained alive and progression free after 5 years of treatment initiation. In these patients, overall survival (OS) rate at 10 years was 60.8% as compared with 11.8% for those progressing within the first 5 years. Hemoglobin (Hb) = 12 g/dl (OR 2.74, p = 0.001) and MGUS-like profile (OR 4.18, p = 0.005) were the two baseline variables associated with long-term disease-free survival. Upon including depth of response (and MRD), Hb = 12 g/dl (OR 2.27) and MGUS-like signature (OR 7.48) retained their predictive value along with MRD negativity (OR 5.18). This study shows that despite the use of novel agents, the probability of disease control at 5 years is still restricted to a small fraction (18.6%) of elderly MM patients. Since this endpoint is associated with higher rates of OS, this study provides important information about diagnostic and post-treatment biomarkers helpful in predicting the likelihood of disease control at 5 years.
000078839 536__ $$9info:eu-repo/grantAgreement/EUR/ERC/MYELOMANEXU-2015$$9info:eu-repo/grantAgreement/ES/ISCIII/CB16-12-00369$$9info:eu-repo/grantAgreement/ES/ISCIII/CB16-12-00377$$9info:eu-repo/grantAgreement/ES/ISCIII/CIBERONC$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/CD13-00340$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/G03-136$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI12-01761$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI12-02311$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI13-01469$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI14-01867$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/PS09-01897-01370
000078839 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000078839 590__ $$a8.023$$b2019
000078839 592__ $$a2.924$$b2019
000078839 591__ $$aONCOLOGY$$b25 / 244 = 0.102$$c2019$$dQ1$$eT1
000078839 593__ $$aOncology$$c2019$$dQ1
000078839 591__ $$aHEMATOLOGY$$b6 / 76 = 0.079$$c2019$$dQ1$$eT1
000078839 593__ $$aHematology$$c2019$$dQ1
000078839 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000078839 700__ $$aMateos, M.V.
000078839 700__ $$aMartínez-López, J.
000078839 700__ $$aHernández, M.T.
000078839 700__ $$aOcio, E.M.
000078839 700__ $$aRosiñol, L.
000078839 700__ $$aMartínez, R.
000078839 700__ $$aTeruel, A.I.
000078839 700__ $$aGutiérrez, N.C.
000078839 700__ $$aBargay, J.
000078839 700__ $$aBengoechea, E.
000078839 700__ $$aGonzález, Y.
000078839 700__ $$ade Oteyza, J.P.
000078839 700__ $$aGironella, M.
000078839 700__ $$aNuñez-Córdoba, J.M.
000078839 700__ $$aEncinas, C.
000078839 700__ $$aMartín, J.
000078839 700__ $$aCabrera, C.
000078839 700__ $$0(orcid)0000-0001-8515-3599$$aPalomera, L.$$uUniversidad de Zaragoza
000078839 700__ $$ade Arriba, F.
000078839 700__ $$aCedena, M.T.
000078839 700__ $$aPuig, N.
000078839 700__ $$aOriol, A.
000078839 700__ $$aPaiva, B.
000078839 700__ $$aBladé, J.
000078839 700__ $$aLahuerta, J.J.
000078839 700__ $$aSan Miguel, J.F.
000078839 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000078839 773__ $$g9, 4 (2019), 36$$pBLOOD CANCER JOURNAL$$tBLOOD CANCER JOURNAL$$x2044-5385
000078839 8564_ $$s151944$$uhttps://zaguan.unizar.es/record/78839/files/texto_completo.pdf$$yVersión publicada
000078839 8564_ $$s99783$$uhttps://zaguan.unizar.es/record/78839/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000078839 909CO $$ooai:zaguan.unizar.es:78839$$particulos$$pdriver
000078839 951__ $$a2020-07-16-08:44:11
000078839 980__ $$aARTICLE